Summary by Moomoo AI
Kozai Pharmaceuticals-B (share code: 2171) will hold its Annual General Meeting in Shanghai on 21 May 2024, at which time a number of motions will be considered, including the approval of the 2023 financial statements and the reports of directors and auditors. The agenda also includes the re-election of Executive Directors Dr. Li Zonghai and Dr. Wang Huamao, Non-Executive Director Mr. Guo Pingsen, and Ms. Zhao, Independent Non-Executive Director. In addition, the discussion will be given to authorise the Board to determine the remuneration of directors, to renew EY as auditor and its remuneration, and to grant the directors general authority to issue and repurchase shares. The Special Resolution includes the approval of amendments to the Articles of Association and the adoption of the revised and revised Organization Statutes and Conditions. SHAREHOLDERS MAY APPOINT REPRESENTATIVES TO ATTEND THE GENERAL MEETING AND VOTE. THE FORM OF PROXY MUST BE SENT TO HONG KONG CENTRAL SECURITIES REGISTRY LIMITED BY 19 MAY 2024.